Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

SRI’s Oncology Candidate Wins Development Support from NCI

  • SRI International received support from the NCI thus gaining access to the drug development resources of the Developmental Therapeutics Program. The company will use these assets to further the preclinical development of its drug to treat advanced cancers. SR16388, a novel antiangiogenic drug, is being investigated for the treatment of multiple tumor types, including metastatic prostate cancer.

    "SR16388 is the third SRI drug candidate to be awarded development support from the National Cancer Institute," points out Nathan Collins, Ph.D., executive director of drug discovery in SRI's biosciences division.

    The contract was won through NCI’s Rapid Access to Intervention Development, a peer-reviewed competitive award program designed to assist translation of novel anticancer therapeutics to the clinic.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »